Epirus, Polpharma Team To Develop, Sell Rheumatoid Arthritis Biosimilars

Partners plan to bring infliximab biosimilar to market in emerging markets this year, with plans for U.S. and EU versions by 2017, then adalimumab and tocilizumab biosimilars globally in 2018 and 2019, respectively.